HK1205191A1 - Aav vector compositions and methods for gene transfer to cells, organs and tissues aav - Google Patents

Aav vector compositions and methods for gene transfer to cells, organs and tissues aav

Info

Publication number
HK1205191A1
HK1205191A1 HK15105905.6A HK15105905A HK1205191A1 HK 1205191 A1 HK1205191 A1 HK 1205191A1 HK 15105905 A HK15105905 A HK 15105905A HK 1205191 A1 HK1205191 A1 HK 1205191A1
Authority
HK
Hong Kong
Prior art keywords
aav
organs
tissues
cells
methods
Prior art date
Application number
HK15105905.6A
Other languages
English (en)
Chinese (zh)
Inventor
Katherine A High
Federico Mingozzi
Junwei Sun
Philip Johnson
Original Assignee
Philadelphia Children Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48984822&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1205191(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Philadelphia Children Hospital filed Critical Philadelphia Children Hospital
Publication of HK1205191A1 publication Critical patent/HK1205191A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK15105905.6A 2012-02-17 2015-06-22 Aav vector compositions and methods for gene transfer to cells, organs and tissues aav HK1205191A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261600415P 2012-02-17 2012-02-17
PCT/US2013/026695 WO2013123503A1 (en) 2012-02-17 2013-02-19 Aav vector compositions and methods for gene transfer to cells, organs and tissues

Publications (1)

Publication Number Publication Date
HK1205191A1 true HK1205191A1 (en) 2015-12-11

Family

ID=48984822

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105905.6A HK1205191A1 (en) 2012-02-17 2015-06-22 Aav vector compositions and methods for gene transfer to cells, organs and tissues aav

Country Status (17)

Country Link
US (2) US20150111955A1 (ja)
EP (1) EP2814958B1 (ja)
JP (2) JP6373763B2 (ja)
KR (1) KR102057540B1 (ja)
CN (1) CN104520428B (ja)
AU (1) AU2013221212B2 (ja)
BR (1) BR112014020325A2 (ja)
CA (1) CA2864879C (ja)
CL (1) CL2014002198A1 (ja)
ES (1) ES2752191T3 (ja)
HK (1) HK1205191A1 (ja)
IL (1) IL234148B (ja)
MX (1) MX367100B (ja)
RU (1) RU2653444C2 (ja)
SG (1) SG11201404956PA (ja)
WO (1) WO2013123503A1 (ja)
ZA (1) ZA201406065B (ja)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2406745C (en) 2001-11-13 2006-01-10 The Trustees Of The University Of Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
CA3066596A1 (en) 2010-04-23 2011-10-27 University Of Massachusetts Cns targeting aav vectors and methods of use thereof
CA3050894C (en) 2010-04-23 2022-10-18 University Of Massachusetts Multicistronic expression constructs
WO2012149259A1 (en) 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce antibody responses
CA2856137A1 (en) * 2011-11-22 2013-05-30 The Children's Hospital Of Philadelphia Virus vectors for highly efficient transgene delivery
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US9539307B2 (en) 2012-09-17 2017-01-10 The Research Institute At Nationwide Children's Hospital Compositions and methods for treating amyotrophic lateral sclerosis
KR102527259B1 (ko) 2013-03-15 2023-04-27 더 칠드런스 호스피탈 오브 필라델피아 스터퍼/필러 폴리누클레오티드 서열을 포함하는 벡터 및 사용 방법
EA201592103A3 (ru) 2013-05-03 2016-08-31 Селекта Байосайенсиз, Инк. Способы и композиции для усиления cd4+ регуляторных t-клеток
DK3024498T3 (da) 2013-07-22 2020-03-02 Childrens Hospital Philadelphia Aav-variant og sammensætninger, fremgangsmåder og anvendelser til genoverførsel til celler, organer og væv
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
AU2014346987A1 (en) 2013-11-05 2016-06-23 The Research Institute At Nationwide Children's Hospital Compositions and methods for inhibiting NF-kB and SOD-1 to treat amyotrophic lateral sclerosis
US10072251B2 (en) 2014-02-19 2018-09-11 University Of Massachusetts Recombinant AAVS having useful transcytosis properties
CA2942515A1 (en) 2014-03-18 2015-09-24 University Of Massachusetts Raav-based compositions and methods for treating amyotrophic lateral sclerosis
FI3628334T3 (fi) * 2014-03-21 2023-09-15 Genzyme Corp Geenihoito verkkokalvon pigmenttirappeuma
ES2876409T3 (es) 2014-04-25 2021-11-12 Univ Pennsylvania Variantes del RLBD y su uso en composiciones para reducir los niveles de colesterol
EP3134522B1 (en) * 2014-04-25 2021-10-06 University of Massachusetts Recombinant aav vectors useful for reducing immunity against transgene products
US10689653B2 (en) 2014-06-03 2020-06-23 University Of Massachusetts Compositions and methods for modulating dysferlin expression
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
CN105396143B (zh) * 2014-09-01 2020-06-26 江苏命码生物科技有限公司 埃博拉病毒特异性的miRNA以及通过miRNA抑制埃博拉病毒的方法
CN106714826A (zh) 2014-09-07 2017-05-24 西莱克塔生物科技公司 用于减弱基因表达调节抗病毒转移载体免疫应答的方法和组合物
US10370432B2 (en) 2014-10-03 2019-08-06 University Of Massachusetts Heterologous targeting peptide grafted AAVS
EP3795580A1 (en) 2014-10-03 2021-03-24 University of Massachusetts High efficiency library-identified aav vectors
CN107073051B (zh) 2014-10-21 2021-08-24 马萨诸塞大学 重组aav变体及其用途
WO2016073693A2 (en) 2014-11-05 2016-05-12 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
SG11201703419UA (en) 2014-11-14 2017-05-30 Voyager Therapeutics Inc Modulatory polynucleotides
US10597660B2 (en) 2014-11-14 2020-03-24 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
US10584321B2 (en) 2015-02-13 2020-03-10 University Of Massachusetts Compositions and methods for transient delivery of nucleases
EP3285780A4 (en) 2015-04-24 2018-12-19 University of Massachusetts Modified aav constructions and uses thereof
CN108289932A (zh) 2015-05-22 2018-07-17 D·D·格恩金 胞外dna作为神经变性的治疗靶点
US10799566B2 (en) 2015-06-23 2020-10-13 The Children's Hospital Of Philadelphia Modified factor IX, and compositions, methods and uses for gene transfer to cells, organs, and tissues
BR112018006074A2 (pt) 2015-09-24 2018-10-09 Biomarin Pharm Inc vetores de fator viii de vírus adeno-associado, partículas virais associadas e formulações terapêuticas compreendendo as mesmas
PL3365438T3 (pl) * 2015-10-21 2021-10-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Zoptymalizowane względem kodonów cdna atp7a o zmniejszonej wielkości i zastosowania w leczeniu zaburzeń transportu miedzi
WO2017070525A1 (en) 2015-10-22 2017-04-27 University Of Massachusetts Methods and compositions for treating metabolic imbalance in neurodegenerative disease
US11426469B2 (en) 2015-10-22 2022-08-30 University Of Massachusetts Prostate-targeting adeno-associated virus serotype vectors
SG10202106307UA (en) 2015-11-13 2021-07-29 Takeda Pharmaceuticals Co Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
CN108602876B (zh) 2015-11-13 2022-07-05 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
MX2018006682A (es) * 2015-12-01 2018-09-26 Spark Therapeutics Inc Metodos escalables para producir vector viral adenoasociado (aav) recombinante en un sistema de cultivo celular en suspension libre de suero adecuado para su uso clinico.
CA3006569A1 (en) 2015-12-02 2017-06-08 Voyager Therapeutics, Inc. Assays for the detection of aav neutralizing antibodies
CA3008142A1 (en) * 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Gene therapy for treating familial hypercholesterolemia
US11826433B2 (en) 2016-02-02 2023-11-28 University Of Massachusetts Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system
CA3012344A1 (en) 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
US20190078099A1 (en) * 2016-03-30 2019-03-14 Spark Therapeutics, Inc. Cell line for recombinant protein and/or viral vector production
US11207426B2 (en) 2016-04-05 2021-12-28 University Of Massachusetts Compositions and methods for selective inhibition of grainyhead-like protein expression
CN117384964A (zh) * 2016-04-15 2024-01-12 全国儿童医院研究所 腺相关病毒载体递送β-肌聚糖和微RNA-29以及肌营养不良症的治疗
US11413356B2 (en) 2016-04-15 2022-08-16 University Of Massachusetts Methods and compositions for treating metabolic imbalance
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
ES2941502T3 (es) 2016-05-13 2023-05-23 4D Molecular Therapeutics Inc Variantes de cápsides de virus adenoasociado y procedimientos de utilización de las mismas
KR20240056729A (ko) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
EP3458589A4 (en) 2016-05-18 2020-01-01 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE
WO2017218852A1 (en) 2016-06-15 2017-12-21 University Of Massachusetts Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
WO2018022511A1 (en) 2016-07-25 2018-02-01 The Trustees Of The University Of Pennsylvania Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
US11584780B2 (en) 2016-07-26 2023-02-21 Biomarin Pharmaceutical Inc. Adeno-associated virus capsid proteins
US20190185864A1 (en) 2016-08-23 2019-06-20 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
CN106344932B (zh) * 2016-08-26 2019-12-27 首都医科大学附属北京同仁医院 一种用于提高视网膜退行性疾病基因治疗效果的组合物及其应用
CN110650673B (zh) 2016-08-30 2024-04-09 加利福尼亚大学董事会 用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
JP2019530463A (ja) 2016-10-13 2019-10-24 ユニバーシティ オブ マサチューセッツ Ａａｖカプシド設計
WO2018082093A1 (en) * 2016-11-07 2018-05-11 Wuhan Institute Of Virology, Chinese Academy Of Sciences Anterograde monosynaptic transneuronal tracer system
US20230190958A1 (en) 2017-01-13 2023-06-22 Jichi Medical University AAV Vector for Disrupting Coagulation Factor-Related Gene on Liver Genome
AU2018220212A1 (en) 2017-02-20 2019-08-08 The Trustees Of The University Of Pennsylvania Gene therapy for treating familial hypercholesterolemia
CN110612122A (zh) 2017-03-11 2019-12-24 西莱克塔生物科技公司 与用抗炎剂和包含免疫抑制剂之合成纳米载体进行的组合治疗相关的方法和组合物
MD3596222T2 (ro) * 2017-03-17 2023-08-31 Res Inst Nationwide Childrens Hospital Livrarea cu vector de virus adeno-asociat a micro-distrofinei specifică mușchiului pentru tratarea distrofiei musculare
MX2019011772A (es) 2017-04-03 2020-01-09 Encoded Therapeutics Inc Expresion transgenica selectiva de tejidos.
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
US11603542B2 (en) 2017-05-05 2023-03-14 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
AU2018264996A1 (en) 2017-05-09 2019-12-05 University Of Massachusetts Methods of treating Amyotrophic Lateral Sclerosis (ALS)
MA49153A (fr) * 2017-05-19 2021-03-24 Encoded Therapeutics Inc Éléments régulateurs à haute activité
CN110945127A (zh) 2017-05-22 2020-03-31 百深公司 用于血友病b的基因疗法的编码具有增加的表达的重组fix的病毒载体
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
EP3654860A1 (en) 2017-07-17 2020-05-27 Voyager Therapeutics, Inc. Trajectory array guide system
EP3655001A4 (en) * 2017-07-17 2021-04-28 Spark Therapeutics, Inc. APHERESIS METHODS AND ASSOCIATED USES
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
CN111727256A (zh) * 2017-09-08 2020-09-29 波赛达治疗公司 用于嵌合配体受体（clr）-介导的条件性基因表达的组合物和方法
CR20200165A (es) 2017-09-20 2020-06-05 4D Molecular Therapeutics Inc Variantes de cápsides de virus adenoasociados y métodos de uso de estas
JP7397488B2 (ja) 2017-09-22 2023-12-13 ユニバーシティ オブ マサチューセッツ Ｓｏｄ１二重発現ベクターおよびその使用
AU2018352236A1 (en) 2017-10-16 2020-04-23 The Curators Of The University Of Missouri Treatment of amyotrophic lateral sclerosis (ALS)
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
CN107760719B (zh) * 2017-10-24 2020-09-22 北京领柯生物科技有限公司 柯萨奇病毒在过继免疫基因递送系统中的应用
AU2018372235B9 (en) 2017-11-27 2022-03-10 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and use for inhibiting angiogenesis
CA3085945A1 (en) * 2017-12-19 2019-06-27 The University Of North Carolina At Chapel Hill Methods and compositions for delivery of viral vectors across the blood-brain barrier
SG11202006169PA (en) * 2017-12-29 2020-07-29 Helixmith Co Ltd Adeno-associated virus (aav) vector having hybrid hgf gene introduced thereto
AU2019209770A1 (en) 2018-01-16 2020-09-03 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
US11306329B2 (en) 2018-02-19 2022-04-19 City Of Hope Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
AU2019249890A1 (en) 2018-04-05 2020-09-24 Association Institut De Myologie Hybrid recombinant adeno-associated virus serotype between AAV9 and AAVrh74 with reduced liver tropism
KR20210008501A (ko) 2018-05-09 2021-01-22 바이오마린 파머수티컬 인크. 페닐케톤뇨증을 치료하는 방법
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
TW202039546A (zh) 2019-01-16 2020-11-01 美商巴克斯歐塔公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
SG11202107744SA (en) * 2019-02-12 2021-08-30 Spacecraft Seven Llc Gene therapy vectors for treatment of danon disease
AU2020229085A1 (en) 2019-02-25 2021-08-19 Friedrich Miescher Institute For Biomedical Research Compositions and methods to treat bietti crystalline dystrophy
CN113474461A (zh) 2019-02-25 2021-10-01 诺华股份有限公司 治疗bietti晶体营养不良的组合物和方法
CN109999182B (zh) * 2019-03-29 2023-03-07 四川大学华西医院 凝血因子在制备抗肿瘤药物中的应用
WO2021041546A1 (en) 2019-08-27 2021-03-04 Vertex Pharmaceuticals Incorporated Compositions and methods for treatment of disorders associated with repetitive dna
MX2022005869A (es) 2019-11-14 2022-06-14 Biomarin Pharm Inc Tratamiento del angioedema hereditario con vectores de terapia de genes especificos del higado.
CN113025618B (zh) * 2019-12-24 2024-02-06 朗信启昇(苏州)生物制药有限公司 一种x连锁遗传性视网膜劈裂症的基因治疗方案与应用
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
EP4114958A1 (en) 2020-02-21 2023-01-11 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
AR122409A1 (es) 2020-04-03 2022-09-07 Biomarin Pharm Inc Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas
EP4165076A1 (en) 2020-06-15 2023-04-19 Sarepta Therapeutics, Inc. Adeno-associated virus antibodies and fragments thereof
CN111500635B (zh) * 2020-07-02 2020-10-09 北京大学第三医院（北京大学第三临床医学院） 一种包含携带核酸分子的载体的试剂盒
CN111876432B (zh) * 2020-07-29 2022-10-28 舒泰神（北京）生物制药股份有限公司 一组肝靶向新型腺相关病毒的获得及其应用
KR20230043869A (ko) 2020-08-07 2023-03-31 스페이스크래프트 세븐, 엘엘씨 Aav 벡터를 사용한 플라코필린-2(pkp2) 유전자 요법
US20220096606A1 (en) 2020-09-09 2022-03-31 Vertex Pharmaceuticals Incorporated Compositions and Methods for Treatment of Duchenne Muscular Dystrophy
US20230414648A1 (en) 2020-11-06 2023-12-28 Vertex Pharmaceuticals Incorporated Compositions and Methods for Treatment of DM1 with SLUCAS9 and SACAS9
WO2022182957A1 (en) 2021-02-26 2022-09-01 Vertex Pharmaceuticals Incorporated Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/sacas9
WO2022182959A1 (en) 2021-02-26 2022-09-01 Vertex Pharmaceuticals Incorporated Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/slucas9
WO2022204476A1 (en) 2021-03-26 2022-09-29 The Board Of Regents Of The University Of Texas System Nucleotide editing to reframe dmd transcripts by base editing and prime editing
WO2022229851A1 (en) 2021-04-26 2022-11-03 Crispr Therapeutics Ag Compositions and methods for using slucas9 scaffold sequences
WO2022234519A1 (en) 2021-05-05 2022-11-10 Crispr Therapeutics Ag Compositions and methods for using sacas9 scaffold sequences
KR20240014477A (ko) 2021-05-28 2024-02-01 상하이 레제네리드 테라피즈 컴퍼니 리미티드 변이체 캡시드를 갖는 재조합 아데노-연관 바이러스 및 이의 응용
WO2023280175A1 (en) * 2021-07-06 2023-01-12 National Institute Of Biological Sciences, Beijing Methods for treating complex i deficiencies or cancers by modulating gro3p biosynthesis
WO2023018637A1 (en) 2021-08-09 2023-02-16 Vertex Pharmaceuticals Incorporated Gene editing of regulatory elements
WO2023039444A2 (en) 2021-09-08 2023-03-16 Vertex Pharmaceuticals Incorporated Precise excisions of portions of exon 51 for treatment of duchenne muscular dystrophy
TW202332472A (zh) 2021-10-01 2023-08-16 美商拜奧馬林製藥公司 利用ａａｖ基因療法載體進行之遺傳性血管水腫治療及治療性調配物
CA3234231A1 (en) 2021-10-21 2023-04-27 Vertex Pharmaceuticals Incorporated Hypoimmune cells
GB202202628D0 (en) * 2022-02-25 2022-04-13 Babraham Inst Novel use and method comprising IL-2 and a tissue- or organic-specific targeting moiety
TW202345911A (zh) 2022-03-08 2023-12-01 美商維泰克斯製藥公司 用於治療杜興氏肌肉失養症(duchenne muscular dystrophy)之部分外顯子44、50及53之精確切除
WO2023172926A1 (en) 2022-03-08 2023-09-14 Vertex Pharmaceuticals Incorporated Precise excisions of portions of exons for treatment of duchenne muscular dystrophy
WO2023205606A1 (en) 2022-04-18 2023-10-26 Vertex Pharmaceuticals Incorporated Compositions and methods for enhancing aav therapy and decreasing tropism of aav to the liver
CN117247973B (zh) * 2022-04-19 2024-05-10 康霖生物科技（杭州）有限公司 一种用于遗传性凝血因子缺乏病治疗的核酸构建体及其用途
WO2024020352A1 (en) 2022-07-18 2024-01-25 Vertex Pharmaceuticals Incorporated Tandem guide rnas (tg-rnas) and their use in genome editing
WO2024064856A1 (en) 2022-09-22 2024-03-28 Biomarin Pharmaceutical Inc. Treatment of cardiomyopathy with aav gene therapy vectors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6468524B1 (en) 2000-03-22 2002-10-22 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services AAV4 vector and uses thereof
CA2406745C (en) * 2001-11-13 2006-01-10 The Trustees Of The University Of Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
CN112029737A (zh) 2005-04-07 2020-12-04 宾夕法尼亚大学托管会 增强腺相关病毒载体功能的方法
WO2007120542A2 (en) * 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid library and aav capsid proteins
CA3066596A1 (en) * 2010-04-23 2011-10-27 University Of Massachusetts Cns targeting aav vectors and methods of use thereof
ES2562421T3 (es) * 2010-10-12 2016-03-04 The Children's Hospital Of Philadelphia Métodos y composiciones para tratar la hemofilia B
WO2013078316A1 (en) * 2011-11-23 2013-05-30 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
US10799566B2 (en) * 2015-06-23 2020-10-13 The Children's Hospital Of Philadelphia Modified factor IX, and compositions, methods and uses for gene transfer to cells, organs, and tissues

Also Published As

Publication number Publication date
SG11201404956PA (en) 2014-09-26
JP2018121655A (ja) 2018-08-09
EP2814958B1 (en) 2019-08-07
MX2014009975A (es) 2015-02-20
CN104520428B (zh) 2018-09-21
BR112014020325A2 (pt) 2017-08-08
JP2015509711A (ja) 2015-04-02
US11939590B1 (en) 2024-03-26
ES2752191T3 (es) 2020-04-03
KR102057540B1 (ko) 2019-12-19
JP6373763B2 (ja) 2018-08-22
US20150111955A1 (en) 2015-04-23
ZA201406065B (en) 2015-12-23
CA2864879A1 (en) 2013-08-22
EP2814958A1 (en) 2014-12-24
MX367100B (es) 2019-08-05
KR20150005521A (ko) 2015-01-14
EP2814958A4 (en) 2015-11-11
IL234148B (en) 2020-01-30
RU2014137450A (ru) 2016-04-10
AU2013221212A1 (en) 2014-09-04
AU2013221212B2 (en) 2018-08-09
CL2014002198A1 (es) 2015-03-13
CA2864879C (en) 2021-07-20
CN104520428A (zh) 2015-04-15
WO2013123503A1 (en) 2013-08-22
RU2653444C2 (ru) 2018-05-08

Similar Documents

Publication Publication Date Title
IL289249A (en) Modified Aav and preparations, methods and uses for gene transfer to cells, organs and tissues
HK1205191A1 (en) Aav vector compositions and methods for gene transfer to cells, organs and tissues aav
IL256517A (en) Modified factor ix, and preparations, methods and uses for gene transfer to cells, organs and tissues
SG10202007803QA (en) Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
IL228328B (en) Aav vectors without capsid, preparations and methods for vector preparation and gene transfer
EP2925307A4 (en) HYDROXYTYROSOL AND OLEUROPEINE COMPOSITIONS FOR INDUCING DNA DAMAGE, CELL DEATH AND LSD1 INHIBITION
EP2850183A4 (en) COMPOSITIONS AND METHOD FOR MODULATING GENE EXPRESSION
LT2731758T (lt) Konvertuojamoji chirurginės prieigos jungtis
ZA201200303B (en) Heart transfer compositions
PT2804475T (pt) Criopreservação de células, tecidos e órgãos
EP2714709A4 (en) CELL-BASED AND GENE-BASED METHODS FOR ENHANCING CARDIAC FUNCTION
EP2872167A4 (en) TOPICAL FORMULATIONS CONTAINING DNA REPAIR ENZYMES AND METHODS OF USING THE SAME
IL230519A0 (en) Virus-based vector constructs used to transform eukaryotic cells
EP2694085A4 (en) METHODS OF ERADICATING POPULATIONS OF BACTERIAL CELLS
EP2844272A4 (en) METHOD AND COMPOSITIONS FOR INCREASING RED BLOOD BODIES
EP2692867A4 (en) EXPRESSION VECTOR FOR ANIMAL CELLS
IL239529A0 (en) Preparations and methods for creating improved and different cells and organisms
ZA201307857B (en) Culture medium for human mesenclymal stem cells
EP2861738A4 (en) METHODS AND COMPOSITIONS ASSOCIATED WITH THE SMCHD1 GENE
HK1198739A1 (en) Adipose tissue-derived stem cells for veterinary use
EP2880166A4 (en) COMPOSITIONS AND METHODS FOR GENETIC CONSTRUCTIONS
GB201203587D0 (en) Modified bacterial cell
GB201001982D0 (en) Follicle culture
GB201006649D0 (en) Cells, compositions and methods
GB201102831D0 (en) Follicle culture